Biology subjects

Fernandez-Aroca, D. M.

Publications and source records attributed to Fernandez-Aroca, D. M..

5 recordsLinked to original sources

bioRxiv2026

Revisiting AXL as a therapeutic target in soft tissue sarcoma: dubermatinib and bemcentinib effects are largely independent of AXL inhibition

Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies with generally poor prognosis, raising a continued interest in novel therapeutic targets. The TAM-family receptor tyrosine kinase AXL has been proposed as a therapeutic target across several cancer types, including STS. Here we revisit the clinical relevance of AXL in STS by combining in silico analyses with functional and transcriptomic characterisation of two representative AXL inhibitors, dubermatinib and bemcentinib, in the HT-1080 and SK-LMS-1 STS-derived cell models. STS ranked among the tumour types with the highest median AXL mRNA expression across The Cancer Genome Atlas, yet AXL expression was not associated with patient survival. Both dubermatinib and bemcentinib reduced cell viability and induced apoptosis but, unexpectedly, shRNA-mediated AXL knockdown failed to reproduce the antiproliferative effect of either inhibitor and did not modify cellular sensitivity to drugs treatment. Transcriptomic profiling after AXL genetic knockdown showed weak correlation with drug-induced transcriptional changes, with the large majority of drug-regulated genes being AXL-independent and largely specific to each cell line. Our data indicate that although dubermatinib and bemcentinib show clear antitumour activity in STS models, this activity is largely independent from AXL inhibition, suggesting the rationale for AXL-directed therapy may be reconsidered.

cancer biology↗

bioRxiv2025

An epigenomic investigation of atrial fibrillation in a matched left and right atrial human cohort

As the most prevalent cardiac arrythmia, atrial fibrillation is an important contributor to cardiovascular morbidity and mortality. Human population findings increasingly support its complex genetic architecture, with most genetic association signals for atrial fibrillation found in the non-coding genome. In this study, we integrated genome-wide histone modification, gene expression and DNA methylation levels in a paired left and right atrial cohort comprising permanent atrial fibrillation patients and sinus rhythm controls. First, we first identified epigenomic regions enriched in histone H3 lysine 27 acetylation (H3K27ac) across left and right atria from patients and controls, and associated them with differentially expressed genes to derive a set of dysregulated candidate loci - including NPPB and SCX. Second, by incorporating an independent replication cohort, we were able to validate gene expression and epigenomic differences for a subset of these candidate loci. Third, we profiled base-resolution DNA methylation levels and identified differentially-methylated regions (DMRs) between atrial fibrillation and sinus rhythm samples. Integration of these data with histone modification levels and gene expression allowed us to propose epigenetic mechanisms underlying transcriptomic and epigenomic changes across dysregulated loci, such as disruption of transcription factor binding by DNA methylation at the LRRC4B locus. The data and analyses we report constitute a systematic investigation of gene regulatory alterations across the left and right atria in permanent atrial fibrillation.

genomics↗

bioRxiv2025

Mammalian epigenomic conservation of promoters and enhancers in the heart associates with trait-associated variation and impacts cardiomyocyte phenotypes

Interindividual genetic variation associated with cardiovascular traits and disease is commonly found in the non-coding genome, suggesting regulatory changes underlie many genetic association signals. Mammalian gene regulation is controlled by promoters and enhancers with rapidly divergent activities. However, the interplay between human non- coding genetic variation and regulatory evolution remains largely unexplored. Here, we investigated promoter and enhancer evolution in the mammalian heart using genome-wide epigenomic profiling, intersected these elements with genetic variants associated with cardiovascular traits, and experimentally tested candidate regions in human cardiomyocytes derived from pluripotent stem cells. First, we applied a comparative genomics approach to identify epigenomically-conserved promoters and enhancers in the heart, as well as elements with primate-specific or human-only epigenomic signals. Second, we evaluated the association of common genetic variation and signatures of cell-type specific gene regulation with mammalian epigenomic conservation. We report an enrichment of common genetic variants in epigenomically-conserved promoters and enhancers, which also associate with regulatory pleiotropy across cardiac cell types, and promoter-enhancer contacts in cardiomyocytes. Based on these findings, we selected candidate epigenomically-conserved elements across three cardiovascular genetics loci (KCNH2, CPEB4 and PRKCE), and investigated gene expression and cellular outcomes upon CRISPR/Cas9-mediated deletion of each region in human cardiomyocytes. These analyses inform how mammalian epigenomic conservation associates with specific gene expression contributions and downstream cellular responses, such as cardiomyocyte hypertrophy and sensitivity to hypoxia/reoxygenation. Moreover, the comparative analyses we present here contribute to ongoing efforts to prioritise and functionally characterise cardiovascular association signals from human population genetics.

genomics↗

bioRxiv2024

The signaling axis CDK12-BRCA1 mediates dinaciclib associated radiosensitivity through p53-mediated cellular senescence.

Pan-CDK inhibitors are a new class of targeted therapies that can act on multiple CDKs, with dinaciclib being one of the most promising compounds. Although used as monotherapy, an interesting approach could be to combine it with radiotherapy. Here we show that dinaciclib increases radiosensitivity in some experimental models of lung and colon cancer (A549 or HCT 116) but not in others (H1299 or HT-29). Dinaciclib did not alter responses such as ATM signalling, apoptosis or cell cycle profiling after ionising radiation exposure that have been described for other CDK inhibitors. Mechanistically, inhibition of CDK12 by dinaciclib abolishes BRCA1 expression, which blocks homologous recombination (HR), leaving only the non-homologous end joining repair process (NHEJ), which ultimately promotes the induction of ionising radiation-associated cellular senescence in a p53-dependent manner, explaining the lack of effect observed in some experimental models. In conclusion, our report explains the molecular mechanism involved in this novel therapeutic effect of dinaciclib and provides a rationale for more selective and personalised chemo/radiotherapy treatment according to the genetic background of the tumour. Highlights[tpltrtarr] Dinaciclib is a radiosensitising agent in lung and colon cancer cell lines. [tpltrtarr]Dinaciclib promotes radiosensitivity by inhibiting CDK12 leading to a decrease in BRCA1 expression. [tpltrtarr]Lack of BRCA1 blocks homologous recombination response to DNA damage, enhancing ionising radiation-associated senescence in a p53-dependent fashion. [tpltrtarr]The combination of dinaciclib plus radiotherapy could be a novel treatment for tumours holding functional BRCA1 and p53 signalling.

cancer biology↗

bioRxiv2022

Genetic perturbation of MAPK11 (p38β) promotes radiosensitivity by enhancing IR-associated senescence.

Background and purposeMAPKs are among the most relevant signalling pathways involved in coordinating cell responses to different stimuli. This group includes p38MAPKs, constituted by 4 different proteins with a high sequence homology: MAPK14 (p38), MAPK11 (p38{beta}), MAPK12 (p38{gamma}) and MAPK13 (p38{delta}). Despite their high similarity, each member shows unique expression patterns and even exclusive functions. Thus, analysing protein-specific functions of MAPK members is necessary to unequivocally uncover the roles of this signalling pathway. Here, we investigate the possible role of MAPK11 in the cell response to ionizing radiation (IR). Materials and methodsWe developed MAPK11/14 knockdown through shRNA and CRISPR interference gene perturbation approaches, and analysed the downstream effects on cell responses to ionizing radiation in A549, HCT-116 and MCF-7 cancer cell lines. Specifically, we assessed IR toxicity by clonogenic assays; DNA damage response activity by immunocytochemistry; apoptosis and cell cycle by flow cytometry (Annexin V and propidium iodide, respectively); DNA repair by comet assay; and senescence induction by both X-Gal staining and gene expression of senescence-associated genes by RT-qPCR. ResultsOur findings demonstrate a critical role of MAPK11 in the cellular response to IR by controlling the associated senescent phenotype, and without observable effects on DDR, apoptosis, cell cycle or DNA damage repair. ConclusionOur results highlight MAPK11 as a novel mediator of the cellular response to ionising radiation through the control exerted onto IR-associated senescence. HighlightsO_LIGenetic perturbation of MAPK11, but not MAPK14, promotes radiosensitivity in a panel of tumor cell lines. C_LIO_LIAbrogation of MAPK11 did not modify DNA damage response, proliferation, apoptosis or cell cycle in response to ionizing radiation C_LIO_LIMAPK11 controls ionizing radiation-induced senescence C_LIO_LIMAPK11 expression could be a novel target and biomarker for radiosensitivity C_LI

cancer biology↗